CMR Surgical Revolutionizing Robotic Surgery with the Versius System
Introduction: A New Era in the Operating Room
The world of surgery is undergoing a quiet revolution — and at the heart of it is a Cambridge-based company with a bold mission. CMR Surgical is a British medical device company that has set out to make robotic-assisted minimal access surgery available to every patient, everywhere. Through its flagship product, the Versius Surgical System, CMR Surgical Limited is challenging the norms of how surgery is performed, who can access it, and what the future of healthcare might look like.
Robotic surgery is no longer the stuff of science fiction. It’s happening in operating theatres right now — in NHS hospitals across the UK, in clinics across India and Australia, and increasingly in the United States. And while several players are competing in this space, few have generated the excitement, the investment, and the clinical momentum that CMR Surgical has managed to build in just over a decade.
For anyone following CMR Surgical news, researching the company’s growth, or looking into CMR Surgical careers, this article covers everything worth knowing — from its founding story to its global ambitions.
Company Background and History: Built in Cambridge, Designed for the World
From a Small Team to a Global Unicorn
CMR Surgical Cambridge is where it all started. The company was founded in 2014 by Martin Frost, with a clear and ambitious goal: to question why so many patients around the world were still not benefiting from minimal access surgery, and to do something about it. Minimal access surgery — often called keyhole surgery — offers patients faster recovery times, reduced pain, and shorter hospital stays compared to open surgery. Yet for years, the technology to support it robotically remained expensive, bulky, and largely inaccessible.
Operating out of Evolution Business Park in CMR Surgical Cambridge, the founding team spent years in research and development, filing key patents as early as 2015 for surgical arm mechanisms and drive systems. These innovations would go on to define the Versius system’s uniquely modular and portable architecture.
In March 2018, the company made a notable move — rebranding from its original name, Cambridge Medical Robotics, to CMR Surgical. This shift reflected a company growing beyond its early identity and stepping into a much larger global vision.
By 2019, CMR Surgical Limited had achieved something remarkable for a medtech startup: unicorn status, with a valuation crossing the $1 billion mark. The company also completed its first human surgical procedures that same year, a milestone that validated years of engineering effort. By 2021, the valuation had grown to $3 billion, cementing its place as one of the most valuable private medical technology companies in the world.
For those interested in CMR Surgical companies house records, the company is registered under the name CMR Surgical Limited with company number 08863657, headquartered in Cambridge, England.
The Versius Surgical System: How It Works
A Robot Designed Around the Surgeon — and the Patient
At the core of everything CMR Surgical does is Versius — a next-generation robotic platform that was designed from the ground up to be different from the systems that came before it.
Versius is a small-scale surgical robotic system featuring collaborative arms and bedside units for direct patient access. It offers 3D HD vision, easy-to-adopt instrument control, and a choice of ergonomic working positions. The open console design reduces stress and fatigue for surgeons during long procedures, while also enabling clear communication with the wider surgical team.
What truly sets Versius apart is its modularity. Unlike traditional large-footprint surgical robots that require dedicated operating theatres, Versius consists of independent arms that can be configured based on the needs of each procedure. This makes it adaptable to operating rooms of varying sizes — a critical advantage for hospitals in both high-income and emerging markets.
The system also features port placement flexibility to best suit individual patients, and its design is inspired by the biomechanics of the human arm — allowing for natural, precise movements that support the surgeon’s own skill rather than replacing it.
Versius Plus: The Next Generation of Robotic Surgery
More Capability. More Precision. More Access.
Building on the success of the original Versius system, CMR Surgical has introduced Versius Plus — a significant upgrade that brings expanded capabilities and a broader range of clinical applications.
Versius Plus provides a full range of instruments, including fully articulated standard instruments designed to enhance surgical precision and enable multi-functional use across a wide variety of procedures. The system is part of a broader Versius ecosystem that includes the EIZO CuratOR product and the vLimeLite visualization system.
Crucially, Versius Plus has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now approved for sale in the United States. Its current U.S. indication is cholecystectomy — a common gallbladder removal procedure — in adult patients aged 22 and older who are eligible for soft tissue minimal access surgery.
For CMR Surgical news followers and industry watchers, the U.S. clearance of Versius Plus marks a defining moment. The CEO of CMR Surgical, Massimiliano Colella, has described it as “an exciting new chapter” for the company as it introduces the system to one of the world’s most competitive medical device markets.
FDA Clearance and U.S. Market Entry
A Hard-Earned Milestone with Major Implications
The path to FDA clearance was deliberate and strategic. While the original Versius system received FDA marketing authorization in October 2024 for use in cholecystectomy in adults, the company chose to enter the U.S. market with the more advanced Versius Plus instead.
As Colella explained publicly, the decision reflected deep respect for the U.S. market: entering with anything less than the best available product was simply not an option.
The FDA clearance of Versius Plus adds a significant new voice to the U.S. robotic surgery market, which has long been dominated by Intuitive Surgical and its da Vinci system. More recently, Medtronic’s Hugo robotic-assisted surgery system also received FDA clearance, signaling a broader competitive shift. Hospital systems and healthcare networks in the U.S. now have more choices than ever — and CMR Surgical Limited is positioning itself as a compelling alternative, particularly for institutions that value flexibility, portability, and value-based care.
Surgical Specialties and Clinical Applications
Where Versius Is Making a Difference
One of the most compelling aspects of CMR Surgical’s Versius platform is its clinical versatility. The system has been applied across a wide range of minimal access procedures:
- General surgery: cholecystectomy, colorectal resections
- Gynecology: hysterectomies, pelvic surgeries
- Urology: radical prostatectomies, renal surgeries
- Thoracic surgery: including a successful trial in transthoracic esophagectomy, published in Nature in October 2022
Perhaps most strikingly, Versius has expanded into pediatric surgery. In 2024, a seven-year-old boy named Reece from Gosport, Hampshire, became the first child in the UK to undergo surgery using the Versius Surgical Robotic System. The procedure targeted a kidney condition and was part of a UK NHS-led trial — a powerful demonstration of the system’s growing scope and the trust surgeons are placing in it.
Global Reach and Hospital Partnerships
Surgery Without Borders
CMR Surgical is no longer simply a Cambridge success story. It has grown into a genuinely global business, with a presence in more than 20 countries across Europe, Asia, the Middle East, Africa, Australia, and the Americas.
In the United Kingdom, CMR Surgical Cambridge has established 20 NHS hospital partnerships, including prestigious institutions such as Guy’s and St Thomas’ in London, Royal Papworth in Cambridge, Manchester Royal Infirmary, and the University Hospital of Wales in Cardiff, among many others.
Beyond the UK, the Versius system has gained traction in India, where the 1,000th operation was performed at HCG Manavata Cancer Centre, with surgeons reporting clear patient benefits including reduced pain and shorter hospital stays. In Australia, Macquarie University Hospital introduced Versius for keyhole surgery following approval from the Therapeutic Goods Administration. In Pakistan, the system was adopted for urological procedures in 2022. And in Latin America, the 1,000th regional case marked another milestone in CMR’s international growth story.
As of October 2025, Versius has been used in over 40,000 surgical procedures worldwide — a figure that reflects not just commercial growth, but genuine clinical trust built case by case, hospital by hospital.
Funding, Valuation, and Business Strategy
The Investment Behind the Innovation
Scaling a surgical robotics company to global reach requires significant capital — and CMR Surgical Limited has attracted some of the world’s most sophisticated investors.
In 2021, the company raised $600 million at a $3 billion valuation in a landmark Series D financing round. Escala Capital was the largest investor, followed by SoftBank Vision Fund 2, with notable participation from GE Healthcare and ABB Technology Ventures. CMR Surgical described this as the largest private financing round in the medtech sector at the time.
More recently, CMR Surgical closed a financing round of more than $200 million, backed by existing investors and new investor Trinity, to support its commercial expansion — particularly in the United States and Asia.
And then there’s the question that has been making waves in CMR Surgical news circles: reports emerged in 2025 that the company had brought on advisors to explore a potential sale, with a target valuation of as much as $4 billion. While no deal has been confirmed, industry analysts have noted that CMR Surgical would be an extraordinarily attractive acquisition target for any major medical device company looking to enter or strengthen its position in the soft tissue surgical robotics market.
For those tracking CMR Surgical share price developments, it’s worth noting the company remains privately held — so there is no publicly traded CMR Surgical share price available on open markets at this time. Any valuation figures referenced come from private funding rounds and reported acquisition interest.
Market Context and Competitive Landscape
A Rapidly Growing Market with Room for New Leaders
The timing could hardly be better for a company with Versius in its portfolio. According to forecasts from GlobalData, the global market for robotic surgical systems is expected to grow to $15.8 billion by 2030, driven by increasing demand for surgical precision, an ageing population, and a global shift toward value-based healthcare that prioritizes better patient outcomes and reduced recovery times.
Within this growing market, CMR Surgical has positioned itself as the second-largest player globally in terms of installs and surgical procedures — trailing only Intuitive Surgical, the long-dominant force in the field.
CMR’s key differentiators are clear: a modular, portable design that can fit into existing operating rooms without major infrastructure changes; an open platform that gives hospitals and surgeons flexibility; and a pricing model that makes robotic surgery more accessible in emerging markets where cost is often the biggest barrier to adoption. These aren’t minor advantages — they represent a fundamentally different philosophy about who surgical robotics is for.
Training, Support, and Accessibility
Empowering Surgeons to Succeed with Versius
Technology is only as good as the people using it. CMR Surgical understands this well, which is why the company has invested heavily in surgeon training and ongoing support.
CMR offers comprehensive training programs built around the Versius Trainer simulator, virtual reality modules, and a dedicated eLearning platform. These are complemented by peer-to-peer surgeon support — connecting new Versius users with experienced surgeons who can share real-world guidance and insights.
This investment in training isn’t just about product adoption. It reflects the company’s broader mission: to make robotic minimal access surgery universally accessible and affordable. The training infrastructure CMR has built ensures that hospitals in diverse geographies — from major teaching hospitals in London to emerging-market facilities in Asia and Latin America — can adopt Versius with confidence.
For those considering CMR Surgical careers or CMR Surgical jobs, this commitment to education and accessibility is a strong signal of the company’s culture — one that values impact alongside innovation.
Awards, Recognition, and Notable Achievements
A Company That’s Earning Its Place in History
The accolades have followed the results. In April 2023, CMR Surgical was honoured with the King’s Award for Enterprise in the Innovation category — the first time this prestigious award had been given in that category — recognising the Versius Surgical Robotic System as a genuinely groundbreaking innovation.
The same year, the Engineers Gallery opened at the Science Museum in London, featuring a Versius surgical robot arm and a prototype among its exhibits. It’s a fitting recognition for a product that has moved from university-adjacent startup to museum-worthy engineering achievement in less than a decade.
In 2023, CMR Surgical Limited reported revenues of approximately $67 million, reflecting strong commercial momentum even as the company continued to invest in its next phase of growth.
And perhaps the most human milestone of all: in March 2024, the 20,000th Versius surgical case was performed at East and North Hertfordshire NHS Trust. Every one of those cases represents a real patient who benefited from a less invasive, more precise operation.
Conclusion and Future Outlook: Transforming Surgery. For Good.
CMR Surgical is one of those rare companies that combines genuine technological innovation with a mission that feels urgent and meaningful. Since its founding in CMR Surgical Cambridge in 2014, it has grown from a small team of engineers with a question: why aren’t more patients getting minimal access surgery? — into a global leader in robotic-assisted surgical systems.
With Versius Plus now cleared in the United States, a $200 million-plus funding round behind it, partnerships with 20+ NHS hospitals, and over 40,000 completed procedures worldwide, the company’s trajectory is unmistakably upward.
Looking ahead, the focus is clear: deepen the U.S. footprint, accelerate growth across Asia and emerging markets, and continue expanding Versius into new surgical specialties. For CMR Surgical job seekers and CMR Surgical careers candidates, this growth phase means the company will likely be hiring across engineering, clinical, commercial, and regulatory roles in CMR Surgical Ely and other locations.
For patients, the promise is simpler: better surgery, faster recovery, and access to world-class robotic care — no matter where in the world they happen to live.
To learn more, connect with a CMR Surgical representative or explore the latest CMR Surgical news on the company’s official website.
Also Read: Babylon Health The Rise, Fall, and Legacy of a Digital Healthcare Pioneer
